Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 97,116

Document Document Title
WO/2014/129598A1
A novel use of 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid, which has a protein tyrosine phosphatase 1B (PTP1B) inhibitory effect, Akt activating effect, GSK-3βphosphorylating effect and Aβ1-42-induced τ protein phosp...  
WO/2014/128259A1
The present invention is directed to a pharmaceutical composition or a kit-of-parts and its use in the treatment of burnout syndrome and longevity therapy.  
WO/2014/128223A1
Compounds of formula (I), wherein X, Y, Z, R1-R7, m and n are as defined herein, exhibit 5-HT6 antagonistic activity and are thus useful for the treatment of certain CNS disorders. Methods of use of said compounds are also provided.  
WO/2014/129792A1
The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models w...  
WO/2014/128254A1
The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to therapies of neurodegenerative diseases. More specifically, the present invention relates to interleukin-33 (IL-33), a frag...  
WO/2014/130581A1
Provided herein are methods of treatment of migraine headaches comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.  
WO/2014/128585A1
The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined 5 herein. The compounds of formula I are useful as inhibitors of PDE4 for the treatment...  
WO/2014/129411A1
[Problem] The purpose of the present invention is to provide a pharmaceutical composition containing an antibacterial agent, which is effective in elucidating one cause of dementia, and in treatment thereof. [Solution] The present invent...  
WO/2014/128882A1
A medicine that comprises a compound, or a pharmaceutically acceptable salt thereof, for treating depression accompanied by intrusive cognitive emotion, i.e., so-called anxiety depression, said compound having an anti-noradrenaline effec...  
WO/2014/128486A1
Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases ΙΚΚε and/or TBK-1 in which one of V and W is N, and the other of V and W is C-H; ...  
WO/2014/130894A1
This invention provides compounds, methods and compositions for the treatment of inflammatory diseases, comprising the timely administration of a provided compound, which has a structure related to an endogenously formed lipid mediator. ...  
WO/2014/129990A1
This invention relates to novel (±)1-(Dimethylamino)ethyl substituted 6H-benzo[c]chromen-6-one compounds which are useful as pharmaceutical compositions.  
WO/2014/129744A1
The present invention relates to: a novel four-membered cyclic nitrogen compound capable of being used as an agent for treating or preventing depression, mental disorders, premature ejaculation or neuropathic pain by highly preventing th...  
WO/2014/129989A1
This invention is related with the conversion of xenobiotics to potent ACHE and BCHE inhibitors that have activity comparable to the current ACHE and BCHE inhibitor drugs (i.e., donepezil, rivastigmine, and galantamine).  
WO/2014/127458A1
The current application relates to a liquid pharmaceutical composition for intraoral transmucosal administration of a benzodiazepine drug to a mammal. The composition comprises a physiologically acceptable hydrophobic phase, an eutectic ...  
WO/2014/127735A1
The present invention relates to solid forms of trelagliptin, a preparation method therefor and applications thereof, and relates specifically to six new solid forms of the dipeptidyl peptidase-4 inhibitor trelagliptin and preparation me...  
WO/2014/130258A1
The present disclosure is generally directed to compounds which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKl.  
WO/2014/127459A1
The current application relates to a liquid pharmaceutical composition for intiaoral tiansmucosal admmistiation of a benzodiazepine drag to a mammal The composition comprises a physiologically acceptable hydrophobic phase, a eutectic mix...  
WO/2014/125256A1
Nanoparticle delivery systems for use in targeting biologically active agents to the central nervous system comprise a composition comprising (a) a nanoparticle comprising: (i) a core comprising a metal and/or a semiconductor; and (ii) a...  
WO/2014/126596A1
The neuroprotective multifunctional antioxidants are compounds that contain a 2-diacetylamino-5-hydroxypyrimidine moiety, having the structural formula: wherein R1 is CH2 or C2H4; R2 is H or -OR4 where R4 is H or aryl; and R3a and R3b ar...  
WO/2014/127360A1
Disclosed herein are compounds useful for detecting oxidants in a living cell, in a multicellular organism, or in a cell-free sample. In particular, disclosed herein are bioluminescent reporter compounds, and more particularly, fluorinat...  
WO/2014/127042A1
In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears t...  
WO/2014/125277A1
The invention is based on the finding that microparticles can be produced by conditionally- immortalised cells. The conditionally-immortalised cells may be stem cells. The Examples show the successful harvest of microparticles from condi...  
WO/2014/126486A1
The present invention, comprised of the crude aqueous extract of Dioscorea hispida, an indigenous plant from the Philippines, has been shown to have sedative, anti-inflammatory, and analgesic effects. The sedative effect is comparable to...  
WO/2014/127139A1
This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subjec...  
WO/2014/127201A1
The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17- substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use...  
WO/2014/125276A1
This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically a...  
WO/2014/126199A1
[Problem] To provide a novel activity enhancing agent for oxidized protein hydrolase. [Solution] This oxidized protein hydrolase activity enhancing agent is characterized by containing the extract of at least one type of plant selected f...  
WO/2014/124928A1
The invention relates to the use of extracts from Calendula for the treatment and prevention, or therapy and prophylaxis, of disorders and impairments of cognitive and mental functions and for the improvement of mental and cognitive func...  
WO/2014/125121A1
The present application relates to a composition comprising a selective androgen modulating compound of formula (I) and selective estrogen receptor β agonist of formula (II). The present application also relates to the use of a selectiv...  
WO/2014/126191A1
The present invention addresses the problem of providing a drug having a cognitive function improving effect and antidiabetic effect. A phospholipid compound which contains an unsaturated fatty acid having a cyclopropane ring such as 8-[...  
WO/2014/126979A1
The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, a...  
WO/2014/124560A1
Provided herein are compounds of the formula I: (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions contain...  
WO/2014/126972A1
The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, wherein X is defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therap...  
WO/2014/125340A1
The present invention concerns a liquid smoke composition comprising: propylene glycol and/or sorbitol, glycerine, water and at least one compound useful as a medicament by inhalation. Said composition may be advantageously utilized to s...  
WO/2014/124651A1
The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are ...  
WO/2014/125444A1
Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.  
WO/2014/125397A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1 and R2 are as defined in ...  
WO/2014/127315A1
In alternative embodiments, the invention provides nucleophilic hydroxyimino- acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase...  
WO/2014/122604A1
Disclosed is an extract of Polygonum fagopyrum for use in the prevention or treatment of a condition, disorder or disease involving a reduction in the endogenous testosterone level in males.  
WO/2014/123186A1
The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema3A protein participates, such as a neurode...  
WO/2014/124013A1
The present invention relates to amino diol derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.  
WO/2014/123151A1
The purpose of the invention is to elucidate the mechanism of onset of MSA through identifying a causative gene, and then to discover a treatment method. The invention provides a method for testing the risk of multiple system atrophy of ...  
WO/2014/122474A1
The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceu...  
WO/2014/122405A1
The invention relates to a solid oral pharmaceutical composition containing agomelatine intended for systemic action.  
WO/2014/122184A1
Herein described are deuterated catecholamine derivatives of the general Formula (I) wherein R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichm...  
WO/2014/124458A1
Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.  
WO/2014/121883A1
The present invention relates to novel acetylene derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.  
WO/2014/121885A1
The present invention relates to novel quinoxaline derivatives of formula (I) as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.  
WO/2014/122530A1
Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of Cortisol ...  

Matches 201 - 250 out of 97,116